Sydney A Skupa
Overview
Explore the profile of Sydney A Skupa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitz E, Ridout A, Smith A, Eiken A, Skupa S, Drengler E, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767763
Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies. Moreover,...
2.
Eiken A, Schmitz E, Drengler E, Smith A, Skupa S, Mohan K, et al.
Hemato
. 2024 Oct;
5(3):321-339.
PMID: 39450301
Background: B-cell receptor (BCR) signaling is a central driver in chronic lymphocytic leukemia (CLL), along with the activation of pro-survival pathways (e.g., NF-κB) and aberrant anti-apoptotic mechanisms (e.g., BCL2) culminating...
3.
Zablonski K, Skupa S, Eiken A, Sundaram S, Mavis C, Gu J, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2129-2137.
PMID: 39331474
Chronic lymphocytic leukemia (CLL) remains incurable and its ability to acquire resistance to front-line therapeutics has proved challenging. Bromodomain and extra-terminal proteins, particularly bromodomain-containing protein 4 (BRD4), are integral to...
4.
Smith A, Skupa S, Eiken A, Reznicek T, Schmitz E, Williams N, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38775157
Redundant tumor microenvironment (TME) immunosuppressive mechanisms and epigenetic maintenance of terminal T cell exhaustion greatly hinder functional antitumor immune responses in chronic lymphocytic leukemia (CLL). Bromodomain and extraterminal (BET) proteins...
5.
Eiken A, Smith A, Skupa S, Schmitz E, Rana S, Singh S, et al.
Cancer Res Commun
. 2024 Apr;
4(5):1328-1343.
PMID: 38687198
Significance: SpiD3 demonstrates cytotoxicity in CLL partially through inhibition of NFκB signaling independent of tumor-supportive stimuli. By inducing the accumulation of unfolded proteins, SpiD3 activates the UPR and hinders protein...
6.
Banskota S, Skupa S, El-Gamal D, DAngelo C
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768631
The gut microbiome is increasingly being recognized as an important immunologic environment, with direct links to the host immune system. The scale of the gut microbiome's genomic repertoire extends the...
7.
Smith A, Eiken A, Skupa S, Moore D, Umeta L, Smith L, et al.
Int J Mol Sci
. 2022 Jun;
23(12).
PMID: 35743155
B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironment stimuli that fuel CLL cell growth through an array of survival signaling pathways. Novel small-molecule agents targeting...